Review article · 2013 · Open access

Targeting the PI3K-AKT-mTOR signaling network in cancer

Khurum Hayat Khan, Timothy Anthony Yap, Yan Li, David Cunningham

癌症:英文版, 32(5), 253–265 · Published 5 May 2013 · DOI 10.5732/cjc.013.10057

Open PDFView at the publisherCite this paper

In brief

“Targeting the PI3K-AKT-mTOR signaling network in cancer” is a 2013 review article by Khurum Hayat Khan and 3 co-authors, published in 癌症:英文版. OpenAlex counts 248 citations as of 21 November 2026. It is open access: the full text is free to read at 癌症:英文版.

Citations
248
Most cited in
2018 (28)
Field-weighted impact
1.61
References
79
Authors
4

Abstract

The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer and is important for tumor cell growth and survival. The development of targeted therapies against mTOR, a vital substrate along this pathway, led to the approval of allosteric inhibitors, including everolimus and temsirolimus, for the treatment of breast, renal, and pancreatic cancers. However, the suboptimal duration of response in unselected patients remains an unresolved issue. Numerous novel therapies against critical nodes of this pathway are therefore being actively investigated in the clinic in multiple tumor types. In this review, we focus on the progress of these agents in clinical development along with their biological rationale, the need of predictive biomarkers and various combination strategies, which will be useful in counteracting the mechanisms of resistance to this class of drugs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Khan, K. H., Yap, T. A., Li, Y., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. 癌症:英文版, 32(5), 253–265. https://doi.org/10.5732/cjc.013.10057

MLA 9

Khan, Khurum Hayat, et al. “Targeting the PI3K-AKT-mTOR signaling network in cancer.” 癌症:英文版, vol. 32, no. 5, 2013, pp. 253–265. https://doi.org/10.5732/cjc.013.10057.

Chicago

Khan, Khurum Hayat, Timothy Anthony Yap, Yan Li, and David Cunningham. 2013. “Targeting the PI3K-AKT-mTOR signaling network in cancer.” 癌症:英文版 32 (5): 253–265. https://doi.org/10.5732/cjc.013.10057.

Harvard

Khan, K. H. et al. (2013) ‘Targeting the PI3K-AKT-mTOR signaling network in cancer’, 癌症:英文版, 32(5), pp. 253–265. doi:10.5732/cjc.013.10057.

IEEE

K. H. Khan, T. A. Yap, Y. Li, and D. Cunningham, “Targeting the PI3K-AKT-mTOR signaling network in cancer,” 癌症:英文版, vol. 32, no. 5, pp. 253–265, 2013, doi: 10.5732/cjc.013.10057.

BibTeX

@article{khan2013targeting,
  title     = {{Targeting the PI3K-AKT-mTOR signaling network in cancer}},
  author    = {Khan, Khurum Hayat and Yap, Timothy Anthony and Li, Yan and Cunningham, David},
  journal   = {癌症:英文版},
  year      = {2013},
  volume    = {32},
  number    = {5},
  pages     = {253--265},
  doi       = {10.5732/cjc.013.10057},
  url       = {https://doi.org/10.5732/cjc.013.10057}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171010
20182828
20191919
20202424
20212323
20222020
20231111
20241717
20251515
20261919

Its field-weighted citation impact is 1.61: it has been cited 1.61 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer

  • PI3K/AKT/mTOR pathway
  • mTOR inhibitors
  • allosteric inhibitors
  • everolimus
  • temsirolimus
  • targeted cancer therapy
  • predictive biomarkers
  • drug resistance

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Khan, K. H., Yap, T. A., Li, Y., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. 癌症:英文版, 32(5), 253–265. https://doi.org/10.5732/cjc.013.10057

How many times has this paper been cited?

248 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at 癌症:英文版: sign in and open the PDF from this page.

Who wrote this paper?

Khurum Hayat Khan, Timothy Anthony Yap, Yan Li, David Cunningham.

What is the DOI of this paper?

10.5732/cjc.013.10057, permanently at https://doi.org/10.5732/cjc.013.10057. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.